Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity in Patients with Localised dMMR Solid Tumours
The results of a phase II study of neoadjuvant pembrolizumab for patients with localised mismatch repair deficient/microsatellite instability-high solid tumours